• CoVepiT is a prophylactic vaccine against COVID-19 based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2 in barrier tissues such as the respiratory tract and the lung.
  • The vaccine incorporates optimized peptide fragments (neoepitopes) improved using artificial intelligence algorithms to increase immune response and induce strong memory T cell responses.
  • Selection and generation of SARS-CoV-2 targets (including Spike, M, N, and several non-structural proteins) was based on homology seen in 46,000 SARS-CoV-2 samples isolated worldwide, helping ensure vaccine effectiveness even with future evolution of the virus.
  • CoVepiT is generated using OSE’s proprietary Memopi® technology which has been validated for both safety and efficacy through the step-1 of Phase 3 clinical phase of neoepitope vaccine Tedopi® in patients with non-small lung cancer.

In August 2020, positive data from preclinical and human ex vivo studies with CoVepiT have been published online in BioRxiv :

– Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytes.

– Studies show that CoVepiT provides tissue-resident memory (Trm) sentinel T cell response with long-term protective immunity in barrier tissues such as the respiratory tract and the lung.

– Clinical entry is expected Q1 2021.



The CoVepiT program is based on a clinically-validated technology now shown to induce tissue-resident memory T lymphocytes (Trm) sentinel response against multiple parts of SARS-CoV-2, suggesting it provides a long-term protective immunity, as opposed to transient protection provided by neutralizing antibodies.

In addition, this vaccine is designed to anticipate ongoing recurrent virus mutation and evolution, further adding to its long-term protective potential.

T-cell epitopes were selected based on the natural immunity observed against the Company’s peptides in convalescent COVID-19 patients.

Generated using the OSE’s Memopi® vaccinal technology, which has already shown good tolerance and efficacy in a large number of cancer patients, these data build a strong basis to pursue the development of this 2nd generation of SARS-CoV-2 vaccine focused on memory CD8 T cell technology.